Cost-effectiveness analysis of rivaroxaban for treatment and secondary prevention of venous thromboembolism in the Netherlands.
Marieke HeisenMaarten J TreurHarald E HeemstraEric B W GiesenMaarten J PostmaPublished in: Journal of medical economics (2017)
Rivaroxaban treatment of patients with venous thromboembolism results in health gains and cost savings compared to LMWH/VKA therapy. This conclusion holds for the Dutch setting, both for the societal perspective, as well as the healthcare perspective.